Crescendo Biologics, a UK-based drug developer, has appointed Dani Bach as its non-executive Director, with immediate effect. Bach replaces Rob Woodman as the representative for IP Group, now one of the largest shareholders of the company.
Headquartered in Cambridge, Crescendo is the developer of novel, targeted T-cell engaging therapeutics.
Commenting on his appointment, Bach said: “Crescendo is developing an exciting pipeline of highly differentiated, multi-functional Humabody therapeutics."
"I look forward to bringing my expertise to the role, to help progress the therapeutic potential of these novel products.”
Bach has extensive investment experience in areas ranging from medical devices to protein therapeutics. He is currently partner, Life Sciences at IP Group, having joined Touchstone Innovations in January 2016.
Prior to this, he was managing partner at Aravis, where he co-led the design of the investment strategy, fund raising and investment process. Bach also previously worked at Index Ventures, where he helped to build companies such as Levicept and Versartis.
Kevin Johnson, Chairman of the board of directors at Crescendo Biologics, said: “Dani is a great new addition to Crescendo. Having known him for a long time, I am confident that his substantial experience within healthcare investment will bring considerable value to the board.”
